Core Points - Garden Biologics announced the end of the repurchase application period for "Garden Convertible Bonds" on September 15, 2025 [2] - The total number of repurchase applications for the bonds was 10, with a total repurchase amount of 1,005.12 yuan, including interest and tax [2] - The company has transferred the repurchase funds to the designated account of the Shenzhen branch of China Securities Depository and Clearing Corporation Limited [2] - The funds will be credited to the company's account on September 18, 2025, with the transfer date set for September 19, 2025, and investors will receive the repurchase funds on September 22, 2025 [2]

Core Viewpoint - Garden Biologics announced that investors can choose to sell their "Garden Convertible Bonds" at a price of 100 RMB per bond, excluding interest, which may lead to potential losses for investors [2] Summary by Relevant Sections - **Company Announcement** - Garden Biologics released a notice on September 12, stating that investors have the option to sell their holdings of "Garden Convertible Bonds" at 100 RMB per bond [2] - **Market Performance** - As of the last trading day before the announcement, the closing price of "Garden Convertible Bonds" was 130.978 RMB per bond [2]

Group 1 - The company announced a temporary suspension of conversion rights for its convertible bonds during the repurchase application period [2] - The suspension period will last for five trading days, from September 9, 2025, to September 15, 2025 [2] - Conversion rights will be restored starting September 16, 2025 [2]

Group 1 - The company held the first bondholders' meeting for the "Garden Convertible Bonds" on September 2, 2025, in accordance with relevant regulations and rules [1][2] - A total of 2 bondholders attended the meeting in person, representing 11,031 bonds with an outstanding principal amount of 1,103,100 yuan, which accounts for 0.09% of the total outstanding bond face value [2] - The meeting adopted a combination of on-site voting and communication voting, with the results indicating that all attending bondholders agreed to the proposals presented [2] Group 2 - The legal opinions provided by Beijing Haotian Law Firm confirmed that the meeting's convening and procedures complied with relevant laws and regulations, and the qualifications of the conveners and attendees were valid [2] - The meeting's voting procedures and results were deemed legal and valid according to the legal opinions [2] - The company will keep the legal opinion document available for review [2]

证券代码：300401 证券简称：花园生物 公告编号：2025-029 债券代码：123178 债券简称：花园转债 浙江花园生物医药股份有限公司 关于召开"花园转债"2025年第一次债券持有人会议的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏 浙江花园生物医药股份有限公司（以下简称"公司"）于2025年8月15日召开第七届董 事会第十一次会议，审议通过了《关于召开"花园转债"2025年第一次债券持有人会议的议 案》，会议决定于2025年9月2日（星期二）召开公司2025年第一次债券持有人会议。现将会 议的有关事项通知如下： 一、召开会议的基本情况 部门规章、规范性文件和公司《募集说明书》《债券持有人会议规则》的规定。 同一表决权只能选择现场投票或通讯投票中的一种方式，不能重复投票。 （1）截至2025年8月26日下午深圳证券交易所收市时，在中国证券登记结算有限公司 深圳分公司登记在册的"花园转债"（债券代码：123178）的债券持有人。上述公司债券持 有人均有权通过参加现场会议或通讯方式进行记名投票表决，并可以以书面形式委托代理人 （详见附件一）出席会议 ...

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]